most: an observational study of myelofibrosis and essential thrombocythemia
Published 3 years ago • 392 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
0:46
factors associated with progression to myelofibrosis in patients with essential thrombocythemia
-
2:10
phase i study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
2:08
real-world analysis of the most study: factors impacting progression to mf in patients with et
-
1:01
latest advances in myelofibrosis treatment
-
1:57
surpass et: p1101 in essential thrombocythemia
-
2:24
update on phase iib study of bomedemstat in essential thrombocythemia
-
1:43
updates from a phase ii study of bomedemstat for the treatment of essential thrombocythemia
-
2:44
myelofibrosis: jenson shares his experience
-
2:02:32
all hematology review (internal medicine)
-
9:59
dr. kessler addresses questions about your hematology appointment
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:15
exploring the evolving treatment landscape of myelofibrosis
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
2:41
an overview of the latest advances in hematology
-
1:49
advances in the science and treatment of mpns
-
1:46
the efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia
-
1:17
retrospective real-world study evaluating compassionate use of ponatinib in r/r ph-like all
-
3:44
phase ii study update of navtemadlin in patients with myelofibrosis r/r to ruxolitinib
-
1:30
addressing unmet needs in myelofibrosis: alleviating anemia
-
2:18
results of persist-1 & persist-2 studies of pacritinib vs best alternative therapy in myelofibrosis
-
4:39
imetelstat shows promise in advanced myelofibrosis